

Antonio Uccelli

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3357363/antonio-uccelli-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

224
papers

16,387
citations

56
h-index

125
g-index

251
ext. papers

18,766
ext. citations

6.4
avg. IF

6.47
L-index

#	Paper	IF	Citations
224	Mesenchymal stem cells in health and disease. <i>Nature Reviews Immunology</i> , 2008 , 8, 726-36	36.5	2469
223	Human mesenchymal stem cells modulate B-cell functions. <i>Blood</i> , 2006 , 107, 367-72	2.2	1372
222	Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. <i>Blood</i> , 2005 , 106, 1755-61	2.2	1165
221	C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. <i>Nature Immunology</i> , 2009 , 10, 514-23	19.1	853
220	Immunoregulatory function of mesenchymal stem cells. <i>European Journal of Immunology</i> , 2006 , 36, 2566-73	4.4	436
219	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet, The</i> , 2018 , 391, 1263-1273	40	422
218	Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. <i>Annals of Neurology</i> , 2007 , 61, 219-27	9.4	381
217	Mesenchymal stem cells: a new strategy for immunosuppression?. <i>Trends in Immunology</i> , 2007 , 28, 219-26	14.4	369
216	Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 11064-9	11.5	280
215	Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. <i>Human Molecular Genetics</i> , 2006 , 15, 2813-24	5.6	246
214	Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. <i>Lancet Neurology, The</i> , 2011 , 10, 649-56	24.1	231
213	The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. <i>Neurology</i> , 2004 , 63, 919-21	6.5	221
212	Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 17384-9	11.5	208
211	Human mesenchymal stem cells promote survival of T cells in a quiescent state. <i>Stem Cells</i> , 2007 , 25, 1753-60	5.8	208
210	The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 503-10	5	185
209	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1013-24	5	181
208	Neuroprotective features of mesenchymal stem cells. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 59-64	4.2	165

207	Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 3601-5	11.5	156
206	Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. <i>Journal of Neurochemistry</i> , 2009 , 110, 1674-84	6	149
205	Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. <i>Journal of Leukocyte Biology</i> , 2003 , 73, 584-90	6.5	140
204	Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. <i>Haematologica</i> , 2008 , 93, 339-46	6.6	137
203	Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. <i>Arthritis Research and Therapy</i> , 2007 , 9, 301	5.7	137
202	Interferon- γ -dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2776-86		136
201	Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. <i>Stem Cells</i> , 2009 , 27, 693-702	5.8	129
200	T-cell trafficking in the central nervous system. <i>Immunological Reviews</i> , 2012 , 248, 216-27	11.3	126
199	The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. <i>Annals of the New York Academy of Sciences</i> , 2015 , 1351, 114-26	6.5	123
198	Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. <i>Acta Neuropathologica</i> , 2015 , 130, 279-95	14.3	120
197	Catastrophic NAD ⁺ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. <i>PLoS ONE</i> , 2009 , 4, e7897	3.7	119
196	Why should mesenchymal stem cells (MSCs) cure autoimmune diseases?. <i>Current Opinion in Immunology</i> , 2010 , 22, 768-74	7.8	115
195	Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in common marmosets: the encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic MHC class II molecule. <i>Journal of Immunology</i> , 2000 , 165, 1093-101	5.3	112
194	Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. <i>Molecular Medicine</i> , 2012 , 18, 794-804	6.2	109
193	COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 42, 102120	4	106
192	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017 , 140, 2776-2796	11.2	102
191	Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2004 , 148, 146-53	3.5	101
190	An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. <i>Neurology</i> , 1998 , 51, 609-11	6.5	100

189	Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. <i>Brain</i> , 2003 , 126, 285-91	11.2	99
188	Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1. <i>Stem Cells</i> , 2012 , 30, 2044-53	5.8	98
187	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 835-42	5	95
186	Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis. <i>Neurology</i> , 2017 , 88, 2115-2122	6.5	93
185	Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. <i>Neurology</i> , 2010 , 75, 302-9	6.5	92
184	Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. <i>Neurology</i> , 1998 , 50, 1127-33	6.5	88
183	Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. <i>European Neurology</i> , 2000 , 44, 45-8	2.1	85
182	Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. <i>Bone Marrow Transplantation</i> , 2009 , 43, 821-8	4.4	84
181	Isolated cognitive relapses in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 1035-7	5.5	77
180	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. <i>EBioMedicine</i> , 2021 , 72, 103581	8.8	74
179	Unveiling the enigma of the CNS as a B-cell fostering environment. <i>Trends in Immunology</i> , 2005 , 26, 254-264	4.4	68
178	Demyelination and axonal damage in a non-human primate model of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2001 , 184, 41-9	3.2	68
177	Detrimental and protective action of microglial extracellular vesicles on myelin lesions: astrocyte involvement in remyelination failure. <i>Acta Neuropathologica</i> , 2019 , 138, 987-1012	14.3	67
176	Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen. <i>Journal of Immunology</i> , 1997 , 158, 1428-37	5.3	65
175	The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. <i>Stem Cell Research and Therapy</i> , 2012 , 3, 3	8.3	62
174	Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 367-71	5	62
173	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 590-603	5	58
172	Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis. <i>Journal of Autoimmunity</i> , 2016 , 72, 8-18	15.5	58

171	Fingolimod modulates peripheral effector and regulatory T cells in MS patients. <i>Journal of NeuroImmune Pharmacology</i> , 2013 , 8, 1106-13	6.9	58
170	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 1225-33	5	58
169	Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2016 , 7, 606	8.4	58
168	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , 2019 , 18, 845-856	24.1	56
167	Can we switch microglia phenotype to foster neuroprotection? Focus on multiple sclerosis. <i>Immunology</i> , 2014 , 141, 328-39	7.8	56
166	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , 2018 , 90, e823-e831	6.5	54
165	Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. <i>Stem Cells Translational Medicine</i> , 2016 , 5, 1506-1514	6.9	53
164	The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. <i>BMC Genomics</i> , 2007 , 8, 65	4.5	53
163	Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. <i>Human Gene Therapy</i> , 2001 , 12, 905-20	4.8	52
162	Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. <i>Expert Opinion on Biological Therapy</i> , 2006 , 6, 17-22	5.4	51
161	The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. <i>Patient Preference and Adherence</i> , 2017 , 11, 33-45	2.4	51
160	Mesenchymal stem cells as treatment for MS - progress to date. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 515-9	3.9	50
159	Costs and quality of life of multiple sclerosis in Italy. <i>European Journal of Health Economics</i> , 2006 , 7 Suppl 2, S45-54	3.6	50
158	B-cell differentiation in the CNS of patients with multiple sclerosis. <i>Autoimmunity Reviews</i> , 2005 , 4, 549-54,6	5.6	50
157	Blood-brain barrier alterations in the cerebral cortex in experimental autoimmune encephalomyelitis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012 , 71, 840-54	3.1	49
156	Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection. <i>Immunology Letters</i> , 2015 , 168, 183-90	4.1	48
155	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. <i>Neurology</i> , 2018 , 90, e832-e839	6.5	48
154	Regulation of human mesenchymal stem cell functions by an autocrine loop involving NAD+ release and P2Y11-mediated signaling. <i>Stem Cells and Development</i> , 2011 , 20, 1183-98	4.4	48

153	X-Ray Phase Contrast Tomography Reveals Early Vascular Alterations and Neuronal Loss in a Multiple Sclerosis Model. <i>Scientific Reports</i> , 2017 , 7, 5890	4.9	47
152	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. <i>BMC Neurology</i> , 2014 , 14, 65	3.1	43
151	Patient adherence to and tolerability of self-administered interferon β 1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. <i>BMC Neurology</i> , 2012 , 12, 7	3.1	42
150	Immunotherapy for neurological diseases. <i>Clinical Immunology</i> , 2008 , 128, 294-305	9	42
149	Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. <i>Current Drug Targets</i> , 2013 , 14, 637-43	3	42
148	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019 , 40, 155-165	3.5	42
147	MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. <i>Trials</i> , 2019 , 20, 263	2.8	41
146	Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system. <i>Journal of NeuroImmune Pharmacology</i> , 2013 , 8, 1062-76	6.9	41
145	Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. <i>Arthritis Research</i> , 2005 , 7, R256-67		41
144	Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2000 , 6, 192-3	5	40
143	Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1423-30	5	39
142	Stem cell transplantation in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2010 , 23, 218-25	7.1	39
141	Role of B Cells in Multiple Sclerosis and Related Disorders. <i>Annals of Neurology</i> , 2021 , 89, 13-23	9.4	38
140	Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration. <i>Metabolism: Clinical and Experimental</i> , 2017 , 77, 39-46	12.7	37
139	Is there a role for mesenchymal stem cells in autoimmune diseases?. <i>Autoimmunity</i> , 2008 , 41, 592-5	3	37
138	Immunological patterns identifying disease course and evolution in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2005 , 165, 192-200	3.5	36
137	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). <i>Journal of Neurology</i> , 2017 , 264, 2436-2449	5.5	35
136	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , 2016 , 263, 1727-35	5.5	35

135	Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e377	9.1	35
134	Quantitative assessment of finger motor impairment in multiple sclerosis. <i>PLoS ONE</i> , 2013 , 8, e65225	3.7	35
133	Characterization of the TCRB chain repertoire in the New World monkey <i>Callithrix jacchus</i> . <i>Journal of Immunology</i> , 1997 , 158, 1201-7	5.3	34
132	Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. <i>Neurological Sciences</i> , 2011 , 32, 1223-31	3.5	33
131	Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ. <i>NeuroImage</i> , 2019 , 184, 490-495	7.9	33
130	IFN- γ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 139, 1667-1676	11.5	31
129	Central and peripheral nervous system complications following allogeneic bone marrow transplantation. <i>European Journal of Neurology</i> , 2001 , 8, 77-80	6	31
128	Reward responsiveness and fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 233-40	5	30
127	Quantitative 3D investigation of Neuronal network in mouse spinal cord model. <i>Scientific Reports</i> , 2017 , 7, 41054	4.9	29
126	Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1236-7	5	29
125	Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. <i>Journal of NeuroImmune Pharmacology</i> , 2012 , 7, 665-72	6.9	28
124	Primary varicella zoster infection associated with fingolimod treatment. <i>Neurology</i> , 2011 , 76, 1023-4	6.5	28
123	Cingulum bundle alterations underlie subjective fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 442-7	5	27
122	Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b. <i>Neurological Sciences</i> , 2009 , 30, 21-31	3.5	27
121	Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. <i>Archives of Neurology</i> , 2007 , 64, 1531-3		27
120	Effect of radial shock wave therapy on pain and muscle hypertonia: a double-blind study in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 622-9	5	26
119	Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1133-1137	5	26
118	Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation. <i>Journal of NeuroImmune Pharmacology</i> , 2013 , 8, 944-55	6.9	26

117	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , 2018 , 265, 2851-2860	5.5	24
116	CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice. <i>Neuropharmacology</i> , 2013 , 75, 337-46	5.5	23
115	Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases 2006 , 111, 555-66		23
114	Sirt6 regulates dendritic cell differentiation, maturation, and function. <i>Aging</i> , 2016 , 8, 34-49	5.6	23
113	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. <i>Neurological Sciences</i> , 2017 , 38, 53-59	3.5	22
112	Systemic administration of mesenchymal stem cells increases neuron survival after global cerebral ischemia in vivo (2VO). <i>Neural Plasticity</i> , 2010 , 2010, 534925	3.3	22
111	Autologous stem cell transplantation for severe autoimmune diseases: a 10-year experience. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1110, 455-64	6.5	22
110	Conventional perimetry, short-wavelength automated perimetry, frequency-doubling technology, and visual evoked potentials in the assessment of patients with multiple sclerosis. <i>European Journal of Ophthalmology</i> , 2005 , 15, 730-8	1.9	22
109	Teriflunomide treatment reduces B cells in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e403	9.1	21
108	Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis. <i>JAMA Neurology</i> , 2019 , 76, 866-867	17.2	21
107	Tailoring B cell depletion therapy in MS according to memory B cell monitoring. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	21
106	Role of miRNAs shuttled by mesenchymal stem cell-derived small extracellular vesicles in modulating neuroinflammation. <i>Scientific Reports</i> , 2021 , 11, 1740	4.9	21
105	A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study. <i>Frontiers in Neurology</i> , 2014 , 5, 278	4.1	20
104	Biological markers of the inflammatory phase of multiple sclerosis. <i>Neurological Sciences</i> , 2003 , 24 Suppl 5, S271-4	3.5	20
103	Charcot-Marie-Tooth (CMT) 1a duplication at 17p11.2 in Italian families. <i>Journal of Medical Genetics</i> , 1992 , 29, 492-3	5.8	20
102	Neurological Complications and Noninvasive Multimodal Neuromonitoring in Critically Ill Mechanically Ventilated COVID-19 Patients. <i>Frontiers in Neurology</i> , 2020 , 11, 602114	4.1	20
101	Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer ^Q mice. <i>Cell Death and Differentiation</i> , 2021 , 28, 203-218	12.7	20
100	IFN γ enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism. <i>Cell Death and Disease</i> , 2019 , 10, 85	9.8	19

99	Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice. <i>PLoS ONE</i> , 2019 , 14, e0213508	3.7	19
98	Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. <i>Neurological Sciences</i> , 2011 , 32, 181-2	3.5	19
97	Retinal nerve fibre layer measurements and optic nerve head analysis in multiple sclerosis patients. <i>Eye</i> , 2009 , 23, 407-12	4.4	19
96	COVID-19-related and not related Guillain-Barré syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy. <i>Journal of the Neurological Sciences</i> , 2020 , 418, 117114	3.2	19
95	Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1519-1531	5	19
94	Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter?. <i>Current Stem Cell Research and Therapy</i> , 2011 , 6, 69-72	3.6	18
93	Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN- β . <i>Journal of Immunology</i> , 2012 , 188, 1011-8	5.3	18
92	Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central CCL5 overproduction. <i>British Journal of Pharmacology</i> , 2014 , 171, 2457-67	8.6	16
91	Hereditary motor and sensory neuropathy with myelin unfolding: clinical, genetic and neuropathological study of three cases. <i>Journal of the Neurological Sciences</i> , 1994 , 122, 20-7	3.2	16
90	COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2126-2136	5	16
89	Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population. <i>CNS Drugs</i> , 2020 , 34, 425-432	6.7	15
88	Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation. <i>Stem Cell Research and Therapy</i> , 2015 , 6, 245	8.3	15
87	A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. <i>Clinical and Experimental Immunology</i> , 1998 , 111, 186-92	6.2	15
86	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. <i>Neurological Sciences</i> , 2005 , 26 Suppl 4, S200-3	3.5	15
85	17p11.2 duplication is a common finding in sporadic cases of Charcot-Marie-Tooth type 1. <i>European Neurology</i> , 1994 , 34, 135-9	2.1	15
84	NG2, a common denominator for neuroinflammation, blood-brain barrier alteration, and oligodendrocyte precursor response in EAE, plays a role in dendritic cell activation. <i>Acta Neuropathologica</i> , 2016 , 132, 23-42	14.3	15
83	Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6,	9.1	15
82	Tocilizumab in MOG-antibody spectrum disorder: a case report. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 312-314	4	15

81	Characterization of mouse spinal cord vascular network by means of synchrotron radiation X-ray phase contrast tomography. <i>Physica Medica</i> , 2016 , 32, 1779-1784	2.7	14
80	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 36, 101430	4	14
79	Contact with the bone marrow microenvironment readdresses the fate of transplanted hematopoietic stem cells. <i>Experimental Hematology</i> , 2010 , 38, 968-77	3.1	14
78	Investigation of paroxysmal dystonia in a patient with multiple sclerosis: a transcranial magnetic stimulation study. <i>Clinical Neurophysiology</i> , 2008 , 119, 63-70	4.3	14
77	Antibodies against Epstein-Barr virus and herpesvirus type 6 are associated with the early phases of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2007 , 192, 184-5	3.5	14
76	Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial. <i>Frontiers in Behavioral Neuroscience</i> , 2016 , 10, 28	3.5	14
75	Different MRI patterns in MS worsening after stopping fingolimod. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e566	9.1	13
74	CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	13
73	Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. <i>Frontiers in Neurology</i> , 2019 , 10, 1385	4.1	13
72	Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid-bound form. <i>Journal of the Neurological Sciences</i> , 1993 , 119, 91-8	3.2	13
71	Sirt6 inhibition delays the onset of experimental autoimmune encephalomyelitis by reducing dendritic cell migration. <i>Journal of Neuroinflammation</i> , 2020 , 17, 228	10.1	12
70	Selective impairments of motor sequence learning in multiple sclerosis patients with minimal disability. <i>Brain Research</i> , 2014 , 1585, 91-8	3.7	12
69	Anti-glutamic acid decarboxylase limbic encephalitis without epilepsy evolving into dementia with cerebellar ataxia. <i>Archives of Neurology</i> , 2012 , 69, 1064-6		12
68	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. <i>Neurology</i> , 2020 , 95, e1027-e1040	6.5	11
67	Neurorepair with mesenchymal stem cells: hope or hype?. <i>Lancet Neurology</i> , 2012 , 11, 123-5	24.1	11
66	Mesenchymal stem cells exert a remarkable regenerative effect requiring minimal CNS integration: commentary on: "Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function" by Voulgari-Kokota et al. <i>Experimental Neurology</i> , 2013 , 247, 292-5	5.7	11
65	Immuno-therapeutic potential of haematopoietic and mesenchymal stem cell transplantation in MS. <i>Results and Problems in Cell Differentiation</i> , 2010 , 51, 237-57	1.4	11
64	Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks. <i>Neurological Sciences</i> , 2009 , 30 Suppl 2, S175-7	3.5	11

63	Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. <i>Neurology</i> , 2021 ,	6.5	11
62	EAE in the common marmoset <i>Callithrix jacchus</i> . <i>International MS Journal</i> , 2003 , 10, 6-12		11
61	In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma. <i>Immunology Letters</i> , 2017 , 181, 109-115	4.1	10
60	Alterations of glutamate release in the spinal cord of mice with experimental autoimmune encephalomyelitis. <i>Journal of Neurochemistry</i> , 2010 , 115, 343-52	6	10
59	Myelin basic protein intramolecular spreading without disease progression in a patient with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2000 , 110, 240-3	3.5	10
58	Impact of treatment on cellular immunophenotype in MS: A cross-sectional study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	9
57	Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. <i>BMC Neurology</i> , 2014 , 14, 103	3.1	9
56	Restricted immune responses lead to CNS demyelination and axonal damage. <i>Journal of Neuroimmunology</i> , 2000 , 107, 178-83	3.5	9
55	Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. <i>Lancet Neurology</i> , 2021 , 20, 917-929 ^{24.1}		9
54	Mesenchymal stromal cells and immunity: Introductory overview. <i>Immunology Letters</i> , 2015 , 168, 127-8	4.1	8
53	Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab. <i>European Journal of Neurology</i> , 2020 , 27, 2047-2055	6	8
52	Guillain-Barré syndrome after reactivation of varicella-zoster virus. <i>New England Journal of Medicine</i> , 2001 , 344, 65-6	59.2	8
51	Neuroinflammation induces synaptic scaling through IL-1 β -mediated activation of the transcriptional repressor REST/NRSF. <i>Cell Death and Disease</i> , 2021 , 12, 180	9.8	8
50	Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 623-631	5	7
49	Characterization of the response to myelin basic protein in a non human primate model for multiple sclerosis. <i>European Journal of Immunology</i> , 2001 , 31, 474-479	6.1	7
48	Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential. <i>Immunity</i> , 2021 , 54, 1543-1560.e6	32.3	7
47	Ecological impact of isolated cognitive relapses in MS. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 114-117	5	7
46	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520924595	5	6

45	Adult stem cells for spinal cord injury: what types and how do they work?. <i>Cytotherapy</i> , 2008 , 10, 541-2	4.8	6
44	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies		6
43	Pediatric optic neuritis and anti MOG antibodies: a cohort of Italian patients. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 39, 101917	4	6
42	Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 26, 52-54	4	6
41	Multiple sclerosis and non-communicating syringomyelia: a casual association or linked diseases?. <i>Acta Neurologica Scandinavica</i> , 1999 , 100, 270-3	3.8	5
40	Differential display analysis of murine encephalitogenic mRNA. <i>International Immunology</i> , 1998 , 10, 1819-23	4.3	5
39	Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis. <i>Italian Journal of Neurological Sciences</i> , 1994 , 15, 51-3		5
38	Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	5
37	CSF oligoclonal bands and normal appearing white matter periventricular damage in patients with clinically isolated syndrome suggestive of MS. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 31, 93-96	4	4
36	Corneal epithelial dendritic cells in patients with multiple sclerosis: An in vivo confocal microscopy study. <i>Journal of Clinical Neuroscience</i> , 2020 , 81, 139-143	2.2	4
35	Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status. <i>Journal of NeuroImmune Pharmacology</i> , 2021 , 1	6.9	4
34	Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis 2013 , 433-455		4
33	Neuroprotective Potential of Dendritic Cells and Sirtuins in Multiple Sclerosis.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	4
32	High or increasing serum NFL is predictive of impending multiple sclerosis relapses.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 59, 103535	4	3
31	X-ray Phase Contrast Tomography Serves Preclinical Investigation of Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , 2020 , 14, 584161	5.1	3
30	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. <i>Journal of Neurology</i> , 2021 , 268, 1540-1543	5.5	3
29	Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis. <i>Neurotherapeutics</i> , 2021 , 1	6.4	3
28	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.. <i>EBioMedicine</i> , 2022 , 80, 104042	8.8	3

27	Could arterial spin labelling perfusion imaging uncover the invisible in N-methyl-d-aspartate receptor encephalitis?. <i>European Journal of Neurology</i> , 2019 , 26, e86-e87	6	2
26	18F-Fluorodeoxyglucose Positron Emission Tomography Tracks the Heterogeneous Brain Susceptibility to the Hyperglycemia-Related Redox Stress. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
25	Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of "black holes". <i>European Radiology</i> , 2020 , 30, 3843-3851	8	2
24	Monomethyl fumarate inhibits the NFkB pathway and pro-inflammatory cytokine expression in microglia through HCA2 signaling via the AMPK/Sirt axis. <i>Journal of Neuroimmunology</i> , 2014 , 275, 167-168 ⁵	3.5	2
23	A case of thyroiditis during natalizumab therapy for multiple sclerosis. <i>Journal of Endocrinological Investigation</i> , 2011 , 34, 408-9	5.2	2
22	Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2000 , 6, 192-193	5	2
21	Effects of aging on finger movements in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 37, 101449	4	2
20	Hydroxycarboxylic Acid Receptor 2, a Pleiotropically Linked Receptor for the Multiple Sclerosis Drug, Monomethyl Fumarate. Possible Implications for the Inflammatory Response. <i>Frontiers in Immunology</i> , 2021 , 12, 655212	8.4	2
19	COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. <i>Frontiers in Immunology</i> , 2021 , 12, 704110	8.4	2
18	MiR-142-3p regulates synaptopathy-driven disease progression in multiple sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2021 ,	5.2	2
17	Mesenchymal stem cells instruct a beneficial phenotype in reactive astrocytes. <i>Glia</i> , 2021 , 69, 1204-1215 ⁹		2
16	Ghost spasticity in multiple sclerosis. <i>Journal of Electromyography and Kinesiology</i> , 2020 , 51, 102408	2.5	1
15	Can we kill an extra bird with the same stone?. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, E124-5	4.5	1
14	A major influence of the T cell receptor repertoire as compared to antigen processing-presentation in the selection of myelin basic protein epitopes in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1999 , 96, 241-4	3.5	1
13	Animal Models of Demyelination of the Central Nervous System 1999 , 233-245		1
12	A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment. <i>Genes</i> , 2020 , 11,	4.2	1
11	Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 1628-1641	5.3	1
10	Assessing upper limb function in multiple sclerosis using an engineered glove. <i>European Journal of Neurology</i> , 2020 , 27, 2561-2567	6	1

9	Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study. <i>CNS Drugs</i> , 2021 , 36, 83	6.7	1
8	Characterization of the response to myelin basic protein in a non human primate model for multiple sclerosis. <i>European Journal of Immunology</i> , 2001 , 31, 474-9	6.1	1
7	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 135245852210972	5	1
6	Choroidal Thickness in Multiple Sclerosis: An Optical Coherence Tomography Study.. <i>Journal of Clinical Neurology (Korea)</i> , 2022 , 18, 334-342	1.7	0
5	Neuropathological Advances in Multiple Sclerosis 2007 , 3-9		
4	Circulating lymphocyte subsets after total lymphoid irradiation in chronic progressive multiple sclerosis. <i>Annals of the New York Academy of Sciences</i> , 1993 , 677, 458-61	6.5	
3	Interindividual variability of cranioencephalic relationships as predicted by CT. <i>Journal of Computer Assisted Tomography</i> , 1991 , 15, 647-54	2.2	
2	Experimental autoimmune encephalomyelitis in the common marmoset <i>Callithrix jacchus</i> 1999 , 79-84		
1	Catastrophic NAD ⁺ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE.. <i>Blood</i> , 2009 , 114, 4732-4732	2.2	